Skip to main content

Articles

“Sunshine Is the Best Disinfectant”

David B. Nash, MD, MBA

Original Research

Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas

Kelly F. Bell, PharmD, MSPhr, MS; Katherine Cappell, PhD; Michael Liang, MS; Amanda M. Kong, MPH

Stakeholder Perspective

Real-World Studies in Diabetes Needed to Improve Medication Adherence and Persistence

Brian Caveney, MD, JD, MPH

ASCO 2017 - Chronic Lymphocytic Leukemia

Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma

ASCO 2017 - Chronic Lymphocytic Leukemia

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy

ASCO 2017 - Chronic Lymphocytic Leukemia

iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)

ASCO 2017 - Chronic Lymphocytic Leukemia

Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL

ASCO 2017 - Chronic Lymphocytic Leukemia

CD19 CAR T-Cells Combined with Ibrutinib to Induce Complete Remission in CLL

ASCO 2017 - Chronic Lymphocytic Leukemia

Combination Ibrutinib and Venetoclax for the Treatment of MCL: Primary End Point Assessment of the Phase 2 AIM Study

ASCO 2017 - Chronic Lymphocytic Leukemia

A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas

ASCO 2017 - Chronic Lymphocytic Leukemia

Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)

Page 88 of 245
Results 871 - 880 of 2441